首页 > 最新文献

European Journal of Pharmaceutical Sciences最新文献

英文 中文
Holistic evaluation of particle formation induced by physical stress in liquid peptide solutions 液体多肽溶液中物理应力诱导颗粒形成的整体评价。
IF 4.7 3区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-29 DOI: 10.1016/j.ejps.2026.107455
Patrick Schlossbauer , Stefanie Schopf , Katrin Lindner, Anna Müller, Ingo Presser, Maximilian Wittmann
Insufficient physical stability remains a major challenge regarding the development of liquid therapeutics as aggregation and degradation of the drug substance can lead to patient safety concerns through increased immunogenicity or reduced potency. During its lifetime, a drug product (DP) containing for example a therapeutically active peptide can be exposed to various types of physical stress. Here, several methods to induce diverse forms of physical stress on liquid solutions were developed using a buffer solution and implemented by testing different therapeutically active peptides in a tool formulation. Methods to investigate the influence of stress induction during stirring, different kinds of shaking, pumping, and freezing and thawing of the peptide solutions were investigated. The establishment with buffer solution allowed fine-tuning of the parameters to not damage materials like glass vials and tubing themselves. Repeated peristaltic pumping at 110 rpm for 2 h led to time-dependent formation of subvisible particles (SVPs) in each peptide-containing sample. More peptide-specific results were achieved with stirring experiments at 600 rpm over three days. Shaking in glass vials on an orbital shaker at 420 rpm for 10 days did in most cases not introduce enough stress to trigger any response. When switching to a shaking motion induced by a microplate shaker at 1200 rpm, the distinguishability of samples could be increased over the same period due to increased interfacial stress. Freezing and thawing in glass vials at - 50°C led to the formation of SVPs already in peptide-free solutions, possibly due to glass delamination. Subsequent evaluation of visual appearance, absorbance at 620 nm, peptide concentration and covalently bound multimers revealed further insights into stress-induced particle formation of peptide drugs in solution.
物理稳定性不足仍然是液体疗法发展的主要挑战,因为原料药的聚集和降解可能通过增加免疫原性或降低效力导致患者安全问题。在其生命周期内,含有例如治疗活性肽的药品(DP)可暴露于各种类型的物理应激。在这里,几种方法来诱导不同形式的物理应力在液体溶液中使用缓冲溶液,并通过测试不同的治疗活性肽的工具配方实施。方法考察了多肽溶液在搅拌、不同摇动、泵送、冻融过程中应力诱导的影响。缓冲溶液的建立允许对参数进行微调,以免损坏玻璃小瓶和管本身等材料。以110 rpm重复蠕动泵送2小时,导致每个含肽样品中形成随时间变化的不可见颗粒(svp)。在600转/分的转速下进行三天的搅拌实验,获得了更多的肽特异性结果。在大多数情况下,在轨道振动器上以420转/分的速度摇动玻璃小瓶10天,不会产生足够的应力来触发任何反应。当切换到由微孔板振动筛在1200rpm下引起的振动运动时,由于界面应力的增加,样品的可分辨性可以在相同的时间内增加。在- 50°C的玻璃小瓶中冷冻和解冻导致已经在无肽溶液中形成svp,可能是由于玻璃分层。随后对视觉外观、620nm吸光度、多肽浓度和共价结合多聚体的评价进一步揭示了溶液中应力诱导的多肽药物颗粒形成。
{"title":"Holistic evaluation of particle formation induced by physical stress in liquid peptide solutions","authors":"Patrick Schlossbauer ,&nbsp;Stefanie Schopf ,&nbsp;Katrin Lindner,&nbsp;Anna Müller,&nbsp;Ingo Presser,&nbsp;Maximilian Wittmann","doi":"10.1016/j.ejps.2026.107455","DOIUrl":"10.1016/j.ejps.2026.107455","url":null,"abstract":"<div><div>Insufficient physical stability remains a major challenge regarding the development of liquid therapeutics as aggregation and degradation of the drug substance can lead to patient safety concerns through increased immunogenicity or reduced potency. During its lifetime, a drug product (DP) containing for example a therapeutically active peptide can be exposed to various types of physical stress. Here, several methods to induce diverse forms of physical stress on liquid solutions were developed using a buffer solution and implemented by testing different therapeutically active peptides in a tool formulation. Methods to investigate the influence of stress induction during stirring, different kinds of shaking, pumping, and freezing and thawing of the peptide solutions were investigated. The establishment with buffer solution allowed fine-tuning of the parameters to not damage materials like glass vials and tubing themselves. Repeated peristaltic pumping at 110 rpm for 2 h led to time-dependent formation of subvisible particles (SVPs) in each peptide-containing sample. More peptide-specific results were achieved with stirring experiments at 600 rpm over three days. Shaking in glass vials on an orbital shaker at 420 rpm for 10 days did in most cases not introduce enough stress to trigger any response. When switching to a shaking motion induced by a microplate shaker at 1200 rpm, the distinguishability of samples could be increased over the same period due to increased interfacial stress. Freezing and thawing in glass vials at - 50°C led to the formation of SVPs already in peptide-free solutions, possibly due to glass delamination. Subsequent evaluation of visual appearance, absorbance at 620 nm, peptide concentration and covalently bound multimers revealed further insights into stress-induced particle formation of peptide drugs in solution.</div></div>","PeriodicalId":12018,"journal":{"name":"European Journal of Pharmaceutical Sciences","volume":"219 ","pages":"Article 107455"},"PeriodicalIF":4.7,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146097004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of pyrrolo[2,3-d]pyrimidine-based dual MERTK and FLT3 inhibitor: Hit-to-lead, machine learning, modeling, synthesis, and biological evaluation 基于吡咯[2,3-d]嘧啶的双MERTK和FLT3抑制剂的鉴定:Hit-to-Lead,机器学习,建模,合成和生物学评价。
IF 4.7 3区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-29 DOI: 10.1016/j.ejps.2025.107421
Abdellah Yamani , Paweł Maliszewski , Natalia Piórkowska , Patrycja Olejkowska-Podgórska , Wojciech Pietruś , Mario Luigi Naitana , Agata Mitkowska , Artur Łaszek , Delfina Popiel , Agata Mikołajczyk , Tomasz Kornatowski , Kinga Jastrzębska , Filip Mituła , Jakub Dominowski , Artur Janusz , Michał Górka , Joanna Hucz-Kalitowska , Małgorzata Teska-Kamińska , Aleksandra Stańczak , Monika Delis , Maciej Wieczorek
Overexpression of MERTK and FLT3 plays a crucial role in activating signal transduction pathways in various human hematological malignancies. These signaling pathways have been extensively studied and have shown significant potential as a promising therapeutic target for the treatment of acute myeloid leukemia (AML). In this study, we employed a modern medicinal chemistry approach, hybridizing machine learning (ML) with a bioisosterism strategy, to design and synthesize a new series of pyrrolo[2,3-d] pyridine derivatives as potent dual inhibitors of MERTK and FLT3. Through successive structure-activity relationship (SAR) studies, we successfully identified the lead compound 31l as a highly potent and selective MERTK/FLT3 dual inhibitor. Compound 31l exhibited remarkable kinase inhibitory activity against MERTK and FLT3 with IC50 values of 2.58 and 0.86 nM, respectively, and potential anti-proliferative activity against MOLM-13 cell lines (IC50 value of 7.50 nM). Furthermore, compound 31l displayed a favorable metabolic stability profile in both human and mouse liver microsome screens and an oral bioavailability of 56%. This finding suggests that lead compound 31l is a promising tool for further optimization and development as a potential MERTK/FLT3 dual inhibitor anti-AML drug candidate.
MERTK和FLT3的过表达在激活各种人类血液恶性肿瘤的信号转导途径中起着至关重要的作用。这些信号通路已被广泛研究,并显示出作为治疗急性髓性白血病(AML)的有希望的治疗靶点的巨大潜力。在这项研究中,我们采用现代药物化学方法,将机器学习(ML)与生物等构化策略相结合,设计并合成了一系列新的吡咯[2,3-d]吡啶衍生物,作为MERTK和FLT3的有效双重抑制剂。通过连续的构效关系(SAR)研究,我们成功地鉴定出先导化合物31l是一种高效、选择性的MERTK/FLT3双抑制剂。化合物31l对MERTK和FLT3具有明显的激酶抑制活性,IC50值分别为2.58和0.86 nM,对MOLM-13细胞株具有潜在的抗增殖活性(IC50值为7.50 nM)。此外,化合物31l在人和小鼠肝微粒体筛选中均表现出良好的代谢稳定性,口服生物利用度为56%。这一发现表明,先导化合物31l作为一种潜在的MERTK/FLT3双抑制剂抗aml候选药物,具有进一步优化和开发的潜力。
{"title":"Identification of pyrrolo[2,3-d]pyrimidine-based dual MERTK and FLT3 inhibitor: Hit-to-lead, machine learning, modeling, synthesis, and biological evaluation","authors":"Abdellah Yamani ,&nbsp;Paweł Maliszewski ,&nbsp;Natalia Piórkowska ,&nbsp;Patrycja Olejkowska-Podgórska ,&nbsp;Wojciech Pietruś ,&nbsp;Mario Luigi Naitana ,&nbsp;Agata Mitkowska ,&nbsp;Artur Łaszek ,&nbsp;Delfina Popiel ,&nbsp;Agata Mikołajczyk ,&nbsp;Tomasz Kornatowski ,&nbsp;Kinga Jastrzębska ,&nbsp;Filip Mituła ,&nbsp;Jakub Dominowski ,&nbsp;Artur Janusz ,&nbsp;Michał Górka ,&nbsp;Joanna Hucz-Kalitowska ,&nbsp;Małgorzata Teska-Kamińska ,&nbsp;Aleksandra Stańczak ,&nbsp;Monika Delis ,&nbsp;Maciej Wieczorek","doi":"10.1016/j.ejps.2025.107421","DOIUrl":"10.1016/j.ejps.2025.107421","url":null,"abstract":"<div><div>Overexpression of MERTK and FLT3 plays a crucial role in activating signal transduction pathways in various human hematological malignancies. These signaling pathways have been extensively studied and have shown significant potential as a promising therapeutic target for the treatment of acute myeloid leukemia (AML). In this study, we employed a modern medicinal chemistry approach, hybridizing machine learning (ML) with a bioisosterism strategy, to design and synthesize a new series of pyrrolo[2,3-<em>d</em>] pyridine derivatives as potent dual inhibitors of MERTK and FLT3. Through successive structure-activity relationship (SAR) studies, we successfully identified the lead compound 31l as a highly potent and selective MERTK/FLT3 dual inhibitor. Compound 31l exhibited remarkable kinase inhibitory activity against MERTK and FLT3 with IC<sub>50</sub> values of 2.58 and 0.86 nM, respectively, and potential anti-proliferative activity against MOLM-13 cell lines (IC<sub>50</sub> value of 7.50 nM). Furthermore, compound 31l displayed a favorable metabolic stability profile in both human and mouse liver microsome screens and an oral bioavailability of 56%. This finding suggests that lead compound 31l is a promising tool for further optimization and development as a potential MERTK/FLT3 dual inhibitor anti-AML drug candidate.</div></div>","PeriodicalId":12018,"journal":{"name":"European Journal of Pharmaceutical Sciences","volume":"219 ","pages":"Article 107421"},"PeriodicalIF":4.7,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146096970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to “Novel porphyrin photosensitizer LD4-PDT alleviates asthma airway remodeling by inhibiting EGR1-dependent TGF-β1/Smad signaling” [European Journal of Pharmaceutical Sciences, Volume 218 (2026) 107431] “新型卟啉光敏剂LD4-PDT通过抑制egr1依赖性TGF-β1/Smad信号缓解哮喘气道重塑”的更正[欧洲制药科学杂志,卷218 (2026)107431]
IF 4.7 3区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-28 DOI: 10.1016/j.ejps.2026.107448
Zhuo Tao , Hongzhi Yu , Bin Xu , Xueming Wang , Junping Wu , Ying Wen , Tianjun Liu
{"title":"Corrigendum to “Novel porphyrin photosensitizer LD4-PDT alleviates asthma airway remodeling by inhibiting EGR1-dependent TGF-β1/Smad signaling” [European Journal of Pharmaceutical Sciences, Volume 218 (2026) 107431]","authors":"Zhuo Tao ,&nbsp;Hongzhi Yu ,&nbsp;Bin Xu ,&nbsp;Xueming Wang ,&nbsp;Junping Wu ,&nbsp;Ying Wen ,&nbsp;Tianjun Liu","doi":"10.1016/j.ejps.2026.107448","DOIUrl":"10.1016/j.ejps.2026.107448","url":null,"abstract":"","PeriodicalId":12018,"journal":{"name":"European Journal of Pharmaceutical Sciences","volume":"218 ","pages":"Article 107448"},"PeriodicalIF":4.7,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146185119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Calcitriol-mediated modulation of organic anion transporters: Insights from endogenous biomarkers and methotrexate pharmacokinetics 骨化三醇介导的有机阴离子转运体的调节:来自内源性生物标志物和甲氨蝶呤药代动力学的见解。
IF 4.7 3区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-27 DOI: 10.1016/j.ejps.2026.107454
Dang-Khoa Vo, Thi-Thao-Linh Nguyen, Seul-A Joo, Han-Joo Maeng
This study aimed to investigate the effects of calcitriol on endogenous biomarkers taurine and pyridoxic acid (PDA) associated with the organic anion transporters Oat1 and Oat1/3, respectively, and compare these changes with those observed for the clinical substrate, methotrexate (MTX). Male rats were administered intraperitoneal (i.p.) injections of either vehicle (maize oil) or calcitriol (2.56 nmol/kg/day) for 4 consecutive days. Plasma, urine, and tissue samples were analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Calcitriol markedly increased plasma taurine levels, decreased its urinary excretion, and reduced taurine concentrations in most tissues. In contrast, PDA exhibited only a moderate increase in plasma levels, with no significant change in urinary excretion, but a notable increase in kidney concentrations. Additional probenecid inhibition studies supported the Oat1-mediated modulation. Intravenous (i.v.) pharmacokinetic studies of taurine (10 mg/kg) revealed altered plasma exposure, clearance, and tissue distribution following calcitriol and probenecid inhibition. In addition, calcitriol significantly affected MTX pharmacokinetics, reinforcing its effect on Oat1/3 function. Taurine induced more significant changes than PDA, indicating its greater sensitivity as an endogenous biomarker for Oat1 activity. These findings highlight the modulatory effects of calcitriol on Oat-mediated transport and demonstrate the utility of taurine and PDA as translational biomarkers for investigating transporter-mediated drug-drug interactions in drug development.
本研究旨在研究骨化三醇对内源性生物标志物牛磺酸和吡哆酸(PDA)分别与有机阴离子转运体Oat1和Oat1/3相关的影响,并将这些变化与临床底物甲氨蝶呤(MTX)的变化进行比较。雄性大鼠连续4天腹腔注射玉米油或骨化三醇(2.56 nmol/kg/天)。采用液相色谱-串联质谱(LC-MS/MS)对血浆、尿液和组织样品进行分析。骨化三醇显著增加血浆中牛磺酸水平,减少尿中牛磺酸排泄,降低大多数组织中牛磺酸浓度。相比之下,PDA仅表现出血浆水平的适度增加,尿排泄没有明显变化,但肾脏浓度明显增加。其他的probenecid抑制研究支持了oat1介导的调节。静脉注射(i.v.)牛磺酸(10mg /kg)的药代动力学研究显示,骨化三醇和丙戊酸抑制后,血浆暴露、清除率和组织分布发生了改变。此外,骨化三醇显著影响MTX的药代动力学,增强了其对Oat1/3功能的影响。牛磺酸诱导的变化比PDA更显著,表明其作为Oat1活性内源性生物标志物的敏感性更高。这些发现强调了骨化三醇对燕麦介导的转运的调节作用,并证明了牛磺酸和PDA作为研究转运体介导的药物-药物相互作用的翻译生物标志物在药物开发中的应用。
{"title":"Calcitriol-mediated modulation of organic anion transporters: Insights from endogenous biomarkers and methotrexate pharmacokinetics","authors":"Dang-Khoa Vo,&nbsp;Thi-Thao-Linh Nguyen,&nbsp;Seul-A Joo,&nbsp;Han-Joo Maeng","doi":"10.1016/j.ejps.2026.107454","DOIUrl":"10.1016/j.ejps.2026.107454","url":null,"abstract":"<div><div>This study aimed to investigate the effects of calcitriol on endogenous biomarkers taurine and pyridoxic acid (PDA) associated with the organic anion transporters Oat1 and Oat1/3, respectively, and compare these changes with those observed for the clinical substrate, methotrexate (MTX). Male rats were administered intraperitoneal (i.p.) injections of either vehicle (maize oil) or calcitriol (2.56 nmol/kg/day) for 4 consecutive days. Plasma, urine, and tissue samples were analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Calcitriol markedly increased plasma taurine levels, decreased its urinary excretion, and reduced taurine concentrations in most tissues. In contrast, PDA exhibited only a moderate increase in plasma levels, with no significant change in urinary excretion, but a notable increase in kidney concentrations. Additional probenecid inhibition studies supported the Oat1-mediated modulation. Intravenous (i.v.) pharmacokinetic studies of taurine (10 mg/kg) revealed altered plasma exposure, clearance, and tissue distribution following calcitriol and probenecid inhibition. In addition, calcitriol significantly affected MTX pharmacokinetics, reinforcing its effect on Oat1/3 function. Taurine induced more significant changes than PDA, indicating its greater sensitivity as an endogenous biomarker for Oat1 activity. These findings highlight the modulatory effects of calcitriol on Oat-mediated transport and demonstrate the utility of taurine and PDA as translational biomarkers for investigating transporter-mediated drug-drug interactions in drug development.</div></div>","PeriodicalId":12018,"journal":{"name":"European Journal of Pharmaceutical Sciences","volume":"218 ","pages":"Article 107454"},"PeriodicalIF":4.7,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146085251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Scoping review to identify data needs and environmental hotspots for future LCA Studies: Insights into pharmaceutical excipients and processes 确定未来LCA研究的数据需求和环境热点的范围审查:对药物赋形剂和工艺的见解。
IF 4.7 3区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-27 DOI: 10.1016/j.ejps.2026.107453
Anja Autzen Virtanen , Satu Lakio , Atif Madi , Mia Sivén
In recent years, the environmental assessment and optimization of pharmaceutical dosage forms have received increasing attention. Consequently, interest in Life Cycle Assessments (LCA) has grown, and LCA is rapidly becoming the standard method of environmental evaluations across many industries, including the pharmaceutical sector. LCA is, however, a high entry barrier method requiring expertise, software- and database access, and process specific experimentally obtained performance data (e.g. electricity consumption). In the context of pharmaceuticals, significant challenges arise due to the limited availability of input data. Because of these limitations, we wanted to investigate the feasibility of using a scoping review as an alternative to LCA for evaluating the environmental implications of pharmaceuticals. In this literature review, a total of 8788 articles were screened, of which 117 were relevant. The search was anchored in a formulation previously developed. In this formulation, 3.0 mm minitablets were manufactured by direct compression from a spray-dried amorphous solid dispersion of indomethacin in polyvinylpyrrolidone (PVP) or hydroxypropyl methylcellulose acetate succinate (HPMCAS) with the additional use of milled lactose monohydrate (LACT), microcrystalline cellulose (MCC) and magnesium stearate (MgSt) as tablet excipients. Through the systematic literature review, relevant environmental information was found for most of the processes and excipients investigated. Research currently undertaken at the intersection of environmental review and pharmaceutical manufacturing shows an upward trend. Most notably, recent research indicates that excipients generally regarded as safe (GRAS) may not necessarily be without environmental concern. Furthermore, excipients may be manufactured through multiple different routes which muddles the environmental comparison of different options. Still, this literature review identified a marked absence of sustainability-themed research specific to pharmaceutical manufacturing. With the issues uncovered, more research is sorely needed to provide guidance in formulation choices.
近年来,药物剂型的环境评价与优化越来越受到人们的关注。因此,人们对生命周期评估(LCA)的兴趣日益浓厚,LCA正迅速成为包括制药行业在内的许多行业环境评估的标准方法。然而,LCA是一种进入门槛很高的方法,需要专业知识、软件和数据库访问以及特定过程的实验获得的性能数据(例如电力消耗)。在药品方面,由于输入数据的可用性有限,出现了重大挑战。由于这些限制,我们想研究使用范围审查作为LCA的替代方法来评估药物的环境影响的可行性。本次文献综述共筛选8788篇,其中相关文献117篇。搜索是在先前开发的公式中进行的。在该配方中,用喷雾干燥的无定形固体分散体(聚乙烯吡罗烷酮(PVP)或羟丙基甲基乙酸丁二酸纤维素(HPMCAS))直接压缩制成3.0 mm的微型片剂,另外使用研磨的乳糖一水合物(LACT)、微晶纤维素(MCC)和硬脂酸镁(MgSt)作为片剂辅料。通过系统的文献回顾,发现了大多数研究的工艺和辅料的相关环境信息。目前在环境审查和制药制造交叉领域进行的研究显示出上升趋势。最值得注意的是,最近的研究表明,通常被认为是安全的辅料(GRAS)可能不一定没有环境问题。此外,辅料可以通过多种不同的途径制造,这混淆了不同选择的环境比较。尽管如此,本文献综述确定了明显缺乏可持续发展为主题的研究,具体到制药制造。随着这些问题的发现,迫切需要更多的研究来提供配方选择的指导。
{"title":"Scoping review to identify data needs and environmental hotspots for future LCA Studies: Insights into pharmaceutical excipients and processes","authors":"Anja Autzen Virtanen ,&nbsp;Satu Lakio ,&nbsp;Atif Madi ,&nbsp;Mia Sivén","doi":"10.1016/j.ejps.2026.107453","DOIUrl":"10.1016/j.ejps.2026.107453","url":null,"abstract":"<div><div>In recent years, the environmental assessment and optimization of pharmaceutical dosage forms have received increasing attention. Consequently, interest in Life Cycle Assessments (LCA) has grown, and LCA is rapidly becoming the standard method of environmental evaluations across many industries, including the pharmaceutical sector. LCA is, however, a high entry barrier method requiring expertise, software- and database access, and process specific experimentally obtained performance data (e.g. electricity consumption). In the context of pharmaceuticals, significant challenges arise due to the limited availability of input data. Because of these limitations, we wanted to investigate the feasibility of using a scoping review as an alternative to LCA for evaluating the environmental implications of pharmaceuticals. In this literature review, a total of 8788 articles were screened, of which 117 were relevant. The search was anchored in a formulation previously developed. In this formulation, 3.0 mm minitablets were manufactured by direct compression from a spray-dried amorphous solid dispersion of indomethacin in polyvinylpyrrolidone (PVP) or hydroxypropyl methylcellulose acetate succinate (HPMCAS) with the additional use of milled lactose monohydrate (LACT), microcrystalline cellulose (MCC) and magnesium stearate (MgSt) as tablet excipients. Through the systematic literature review, relevant environmental information was found for most of the processes and excipients investigated. Research currently undertaken at the intersection of environmental review and pharmaceutical manufacturing shows an upward trend. Most notably, recent research indicates that excipients generally regarded as safe (GRAS) may not necessarily be without environmental concern. Furthermore, excipients may be manufactured through multiple different routes which muddles the environmental comparison of different options. Still, this literature review identified a marked absence of sustainability-themed research specific to pharmaceutical manufacturing. With the issues uncovered, more research is sorely needed to provide guidance in formulation choices.</div></div>","PeriodicalId":12018,"journal":{"name":"European Journal of Pharmaceutical Sciences","volume":"219 ","pages":"Article 107453"},"PeriodicalIF":4.7,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146085218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Revealing the Morphology of Small Multilamellar Lipid Nanoparticles (SMLPs) made by In-Vial Homogenization 揭示瓶内均质法制备的小多层脂质纳米颗粒(SMLPs)的形态
IF 4.7 3区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-26 DOI: 10.1016/j.ejps.2026.107451
Sevda Akcesme , Stefanie Schmager , Yassir Al-Tikriti , Lars Gedda , Magnus Bergström , Katarina Edwards , Heiko Heerklotz , Ulrich Massing
Previous research shows that thermosensitive small multilamellar lipid nanoparticles (tSMLPs) offer promising features for temperature-triggered cytostatic drug delivery, remaining completely stable at body temperature (37°C) and releasing their payload under mild hyperthermia conditions (42°C). A distinguishing characteristic of tSMLPs is their unique particle morphology - multiple tightly packed bilayers with progressively decreasing intermembrane spacing toward the particle core. In this study, we shift the focus from their thermosensitivity to an in-depth exploration of the particle’s morphology. Using in-vial homogenization by dual centrifugation (DC) at very high lipid concentrations (60%), we prepare SMLPs composed of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-dipalmitoyl-sn-glycero-3-phosphodiglycerol (DPPG2). A systematic screening of DPPC/DPPG2 100-x/x (mol/mol) from x = 0 to 100 enabled the formation of SMLPs with sizes below 200 nm, narrow size distribution and well-distinguishable morphologies. These lipid nanoparticles also demonstrated the capacity to entrap hydrophilic compounds, despite their multilamellar structure and thus limited interlamellar aqueous space. We propose that specific headgroup interactions between DPPC and DPPG2 underlie the observed water influx upon dilution of the initially formed vesicular phospholipid gels (VPGs) during in-vial homogenization by DC. With a combination of biophysical techniques (DLS, Time-resolved fluorescence, SAXS and WAXS) and morphological analysis (cryo-EM), we present a hypothesis to explain the evolving SMLP morphology as a function of increasing DPPG2 content in the phospholipid blend.
先前的研究表明,热敏小多层脂质纳米颗粒(tSMLPs)为温度触发的细胞抑制药物递送提供了有希望的特性,在体温(37°C)下保持完全稳定,并在轻度高温条件下(42°C)释放其有效载荷。tsmlp的一个显著特征是其独特的颗粒形态-多层紧密排列的双层,膜间间距逐渐减小。在这项研究中,我们将焦点从它们的热敏性转移到对颗粒形态的深入探索。在非常高的脂质浓度(60%)下,使用双离心(DC)的瓶内均质,我们制备了由1,2-双棕榈酰- n-甘油-3-磷酸胆碱(DPPC)和1,2-双棕榈酰- n-甘油-3-磷酸二甘油酯(DPPG2)组成的smlp。系统筛选DPPC/DPPG2 100-x/x (mol/mol),从x = 0到100,可以形成尺寸小于200 nm,尺寸分布窄,形态易于区分的smlp。这些脂质纳米颗粒也显示出捕获亲水化合物的能力,尽管它们是多层结构,因此限制了层间的水空间。我们提出,DPPC和DPPG2之间的特定头基相互作用是DC在瓶内均质过程中稀释初始形成的囊泡磷脂凝胶(VPGs)时观察到的水内流的基础。结合生物物理技术(DLS,时间分辨荧光,SAXS和WAXS)和形态分析(cro - em),我们提出了一个假设来解释SMLP形态的进化是磷脂混合物中DPPG2含量增加的函数。
{"title":"Revealing the Morphology of Small Multilamellar Lipid Nanoparticles (SMLPs) made by In-Vial Homogenization","authors":"Sevda Akcesme ,&nbsp;Stefanie Schmager ,&nbsp;Yassir Al-Tikriti ,&nbsp;Lars Gedda ,&nbsp;Magnus Bergström ,&nbsp;Katarina Edwards ,&nbsp;Heiko Heerklotz ,&nbsp;Ulrich Massing","doi":"10.1016/j.ejps.2026.107451","DOIUrl":"10.1016/j.ejps.2026.107451","url":null,"abstract":"<div><div>Previous research shows that thermosensitive small multilamellar lipid nanoparticles (tSMLPs) offer promising features for temperature-triggered cytostatic drug delivery, remaining completely stable at body temperature (37°C) and releasing their payload under mild hyperthermia conditions (42°C). A distinguishing characteristic of tSMLPs is their unique particle morphology - multiple tightly packed bilayers with progressively decreasing intermembrane spacing toward the particle core. In this study, we shift the focus from their thermosensitivity to an in-depth exploration of the particle’s morphology. Using in-vial homogenization by dual centrifugation (DC) at very high lipid concentrations (60%), we prepare SMLPs composed of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-dipalmitoyl-sn-glycero-3-phosphodiglycerol (DPPG<sub>2</sub>). A systematic screening of DPPC/DPPG<sub>2</sub> 100-x/x (mol/mol) from x = 0 to 100 enabled the formation of SMLPs with sizes below 200 nm, narrow size distribution and well-distinguishable morphologies. These lipid nanoparticles also demonstrated the capacity to entrap hydrophilic compounds, despite their multilamellar structure and thus limited interlamellar aqueous space. We propose that specific headgroup interactions between DPPC and DPPG<sub>2</sub> underlie the observed water influx upon dilution of the initially formed vesicular phospholipid gels (VPGs) during in-vial homogenization by DC. With a combination of biophysical techniques (DLS, Time-resolved fluorescence, SAXS and WAXS) and morphological analysis (cryo-EM), we present a hypothesis to explain the evolving SMLP morphology as a function of increasing DPPG<sub>2</sub> content in the phospholipid blend.</div></div>","PeriodicalId":12018,"journal":{"name":"European Journal of Pharmaceutical Sciences","volume":"218 ","pages":"Article 107451"},"PeriodicalIF":4.7,"publicationDate":"2026-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146090562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Construction of in situ temperature-sensitive gel of Tegafur derivative TAK5399 and its evaluation against breast cancer 替加氟衍生物TAK5399原位温敏凝胶的构建及其抗乳腺癌作用评价。
IF 4.7 3区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-25 DOI: 10.1016/j.ejps.2026.107452
Hong Shao , Wen Li , Zhuohan Li , Peng Shi , Zheng Li , Yuxiang Wang , Chao Pi , Lingmao Zhao , Wenwu Zheng , Yumeng Wei , Ling Zhao
Tegafur (FT) is widely used in the treatment of breast cancer. However, it has poor efficacy and significant toxic side effects. In this study, we first modified FT with aspirin to obtain a new FT derivative, named TAK5399. Then, TAK5399 in situ thermosensitive gel (TAK5399-TSG) was prepared using poloxamer F68 and F127 as carriers, and evaluated in vitro and in vivo. Among the five tested tumor cell lines, TAK5399 exhibited the highest sensitivity toward human breast cancer cells (MCF-7), with an inhibition rate 8.41 times higher than that of FT. Its potential anti-breast cancer mechanism may be related to inhibiting the PI3K/AKT signaling pathway to induce apoptosis and blocking the S phase of the cell cycle. The optimal formulation process for TAK5399-TSG is F127: 24.0%, F68: 6.5%, TAK5399 content of 1.25 mg/mL, and curing time of 24 hours. The maximum drug solubility, gelation temperature, and dissolution time were 1.25 mg/mL, 31 ± 0.21°C, and 6.5 ± 0.25 h, respectively. The Cmax of TAK5399-TSG administered via in situ injection was 15.5% and 23.8% of that of oral and in situ injection of TAK5399, respectively. In tumor-bearing mice, the tumor inhibition rates of oral TAK5399 and in situ injection of TAK5399-TSG were 1.28-fold and 1.82-fold higher than those of oral FT, respectively, with good biocompatibility. In conclusion, TAK5399-TSG is an in situ gel delivery system with potential for the treatment of breast cancer.
替加富(FT)被广泛用于治疗乳腺癌。但其疗效差,毒副作用明显。在本研究中,我们首先用阿司匹林修饰FT,得到一种新的FT衍生物,命名为TAK5399。然后,以波洛沙姆F68和F127为载体制备TAK5399原位热敏凝胶(TAK5399- tsg),并进行体外和体内评价。在5个被测试的肿瘤细胞系中,TAK5399对人乳腺癌细胞(MCF-7)的敏感性最高,抑制率是FT的8.41倍。其潜在的抗乳腺癌机制可能与抑制PI3K/AKT信号通路诱导细胞凋亡,阻断细胞周期S期有关。TAK5399- tsg的最佳配方为:F127: 24.0%, F68: 6.5%, TAK5399含量为1.25 mg/mL,固化时间为24小时。最大药物溶解度为1.25 mg/mL,凝胶温度为31±0.21℃,溶解时间为6.5±0.25 h。原位注射TAK5399- tsg的Cmax分别为口服和原位注射TAK5399的15.5%和23.8%。在荷瘤小鼠中,口服TAK5399和原位注射TAK5399- tsg的抑瘤率分别比口服FT高1.28倍和1.82倍,具有良好的生物相容性。总之,TAK5399-TSG是一种具有治疗乳腺癌潜力的原位凝胶递送系统。
{"title":"Construction of in situ temperature-sensitive gel of Tegafur derivative TAK5399 and its evaluation against breast cancer","authors":"Hong Shao ,&nbsp;Wen Li ,&nbsp;Zhuohan Li ,&nbsp;Peng Shi ,&nbsp;Zheng Li ,&nbsp;Yuxiang Wang ,&nbsp;Chao Pi ,&nbsp;Lingmao Zhao ,&nbsp;Wenwu Zheng ,&nbsp;Yumeng Wei ,&nbsp;Ling Zhao","doi":"10.1016/j.ejps.2026.107452","DOIUrl":"10.1016/j.ejps.2026.107452","url":null,"abstract":"<div><div>Tegafur (FT) is widely used in the treatment of breast cancer. However, it has poor efficacy and significant toxic side effects. In this study, we first modified FT with aspirin to obtain a new FT derivative, named TAK5399. Then, TAK5399 in situ thermosensitive gel (TAK5399-TSG) was prepared using poloxamer F68 and F127 as carriers, and evaluated in vitro and in vivo. Among the five tested tumor cell lines, TAK5399 exhibited the highest sensitivity toward human breast cancer cells (MCF-7), with an inhibition rate 8.41 times higher than that of FT. Its potential anti-breast cancer mechanism may be related to inhibiting the PI3K/AKT signaling pathway to induce apoptosis and blocking the S phase of the cell cycle. The optimal formulation process for TAK5399-TSG is F127: 24.0%, F68: 6.5%, TAK5399 content of 1.25 mg/mL, and curing time of 24 hours. The maximum drug solubility, gelation temperature, and dissolution time were 1.25 mg/mL, 31 ± 0.21°C, and 6.5 ± 0.25 h, respectively. The Cmax of TAK5399-TSG administered via in situ injection was 15.5% and 23.8% of that of oral and in situ injection of TAK5399, respectively. In tumor-bearing mice, the tumor inhibition rates of oral TAK5399 and in situ injection of TAK5399-TSG were 1.28-fold and 1.82-fold higher than those of oral FT, respectively, with good biocompatibility. In conclusion, TAK5399-TSG is an in situ gel delivery system with potential for the treatment of breast cancer.</div></div>","PeriodicalId":12018,"journal":{"name":"European Journal of Pharmaceutical Sciences","volume":"218 ","pages":"Article 107452"},"PeriodicalIF":4.7,"publicationDate":"2026-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146061204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Minimizing Aggregates when Nebulizing Antibody Fab Fragments: High Thermostability and High Concentration are Key. 雾化抗体Fab片段时最大限度地减少聚集:高热稳定性和高浓度是关键。
IF 4.7 3区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-22 DOI: 10.1016/j.ejps.2026.107446
Josi Ann Steinke, Pierre-Louis Destruel, Benjamin Weiche, Stefan Dengl, Gregoire Schwach, Gerhard Pohlmann, Marlon J Hinner

The therapeutic potential of inhaled biologics is limited by protein instability during aerosolization, which can cause aggregation and increase immunogenicity risks. This study aims to identify key molecular and formulation parameters that minimize the aggregation of antibody Fab fragments during vibrating mesh nebulization. A set of 14 engineered Fabs with a broad range of melting temperatures (Tm 60-90°C) were nebulized using two different commercial vibrating mesh devices. We systematically assessed the impact of Fab thermostability, protein concentration (10-80 mg/mL), formulation excipients, and nebulizer device on the formation of high molecular weight species (HMWS) and subvisible particles (SVP). Aerosol characteristics, including fine particle fraction (FPF) and output rate, were also evaluated. High intrinsic thermostability and high protein concentration were identified as the two most critical factors for preventing aggregation. Fabs with a Tm above 80°C demonstrated exceptional stability with negligible aggregation. We attribute this effect to a correlation of high Tm with a higher resistance against unfolding and therefore a better tolerance against nebulization-induced stresses, in particular air/liquid interfacial stress. Counterintuitively, increasing the protein concentration from 10 mg/mL to 80 mg/mL suppressed aggregation for all Fabs, which had the highest benefit for Fabs with lower thermostability. This effect can at least in part be explained by a saturation of the air/liquid interface at higher Fab concentrations. While higher concentrations modestly reduced nebulizer output rates, the overall inhalable protein output (mg protein/min) was significantly enhanced. In comparison, full-length monoclonal antibodies showed poor aerosolization performance at high concentrations. Our findings provide clear guidance for developing inhaled Fab therapeutics. To ensure stability and minimize aggregation, priority should be given to selecting Fabs with high thermostability (Tm > 80°C) and formulating them at high concentrations (≥ 40 mg/mL). These strategies are expected to mitigate aggregation-induced immunogenicity and concomitant safety risks, facilitating the development of the next generation of inhaled protein drugs.

吸入生物制剂的治疗潜力受到雾化过程中蛋白质不稳定的限制,这可能导致聚集并增加免疫原性风险。本研究旨在确定振动网雾化过程中最大限度减少抗体Fab片段聚集的关键分子和配方参数。采用两种不同的商用振动网装置,对14个具有广泛熔化温度(Tm 60-90°C)的工程晶圆厂进行雾化。我们系统地评估了Fab热稳定性、蛋白质浓度(10-80 mg/mL)、配方辅料和雾化器装置对高分子量物质(HMWS)和亚可见颗粒(SVP)形成的影响。气溶胶特性,包括细颗粒分数(FPF)和输出速率也进行了评估。高固有热稳定性和高蛋白质浓度被认为是防止聚集的两个最关键因素。Tm高于80°C的晶圆片表现出优异的稳定性,聚集可以忽略不计。我们将这种效应归因于高Tm与更高的抗展开阻力的相关性,因此对雾化诱导的应力,特别是空气/液体界面应力具有更好的耐受性。与直觉相反,将蛋白浓度从10 mg/mL增加到80 mg/mL抑制了所有fab的聚集,这对热稳定性较低的fab有最大的好处。这种效应至少可以部分解释为在较高的Fab浓度下空气/液体界面的饱和。虽然较高的浓度适度降低了喷雾器的输出速率,但总体可吸入蛋白质输出(mg蛋白/分钟)显着提高。相比之下,全长单克隆抗体在高浓度下表现出较差的雾化性能。我们的发现为开发吸入式Fab疗法提供了明确的指导。为了确保稳定性和减少聚集,应优先选择具有高热稳定性(Tm > 80°C)的晶圆片,并在高浓度(≥40 mg/mL)下配制。这些策略有望减轻聚集诱导的免疫原性和伴随的安全风险,促进下一代吸入蛋白药物的开发。
{"title":"Minimizing Aggregates when Nebulizing Antibody Fab Fragments: High Thermostability and High Concentration are Key.","authors":"Josi Ann Steinke, Pierre-Louis Destruel, Benjamin Weiche, Stefan Dengl, Gregoire Schwach, Gerhard Pohlmann, Marlon J Hinner","doi":"10.1016/j.ejps.2026.107446","DOIUrl":"https://doi.org/10.1016/j.ejps.2026.107446","url":null,"abstract":"<p><p>The therapeutic potential of inhaled biologics is limited by protein instability during aerosolization, which can cause aggregation and increase immunogenicity risks. This study aims to identify key molecular and formulation parameters that minimize the aggregation of antibody Fab fragments during vibrating mesh nebulization. A set of 14 engineered Fabs with a broad range of melting temperatures (T<sub>m</sub> 60-90°C) were nebulized using two different commercial vibrating mesh devices. We systematically assessed the impact of Fab thermostability, protein concentration (10-80 mg/mL), formulation excipients, and nebulizer device on the formation of high molecular weight species (HMWS) and subvisible particles (SVP). Aerosol characteristics, including fine particle fraction (FPF) and output rate, were also evaluated. High intrinsic thermostability and high protein concentration were identified as the two most critical factors for preventing aggregation. Fabs with a T<sub>m</sub> above 80°C demonstrated exceptional stability with negligible aggregation. We attribute this effect to a correlation of high T<sub>m</sub> with a higher resistance against unfolding and therefore a better tolerance against nebulization-induced stresses, in particular air/liquid interfacial stress. Counterintuitively, increasing the protein concentration from 10 mg/mL to 80 mg/mL suppressed aggregation for all Fabs, which had the highest benefit for Fabs with lower thermostability. This effect can at least in part be explained by a saturation of the air/liquid interface at higher Fab concentrations. While higher concentrations modestly reduced nebulizer output rates, the overall inhalable protein output (mg protein/min) was significantly enhanced. In comparison, full-length monoclonal antibodies showed poor aerosolization performance at high concentrations. Our findings provide clear guidance for developing inhaled Fab therapeutics. To ensure stability and minimize aggregation, priority should be given to selecting Fabs with high thermostability (T<sub>m</sub> > 80°C) and formulating them at high concentrations (≥ 40 mg/mL). These strategies are expected to mitigate aggregation-induced immunogenicity and concomitant safety risks, facilitating the development of the next generation of inhaled protein drugs.</p>","PeriodicalId":12018,"journal":{"name":"European Journal of Pharmaceutical Sciences","volume":" ","pages":"107446"},"PeriodicalIF":4.7,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146044020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Design of co-lyophilised ternary insulin-sucrose-polymer systems with enhanced amorphous glass stability 具有增强非晶玻璃稳定性的共冻干三元胰岛素-蔗糖-聚合物体系的设计。
IF 4.7 3区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-22 DOI: 10.1016/j.ejps.2026.107450
Claudia Giannachi , Evin Allen , Sonja Vucen , Abina Crean
The glass stability of lyophilized amorphous peptide formulations, intended for incorporation into solid oral dosage forms, require stabilisation against the challenges of manufacturing, storage and handling temperature and humidity. High glass transition temperature (Tg) polymers, polyvinylpyrrolidone (PVP) and polyvinylpyrrolidone-vinyl acetate (PVPVA), were added to insulin-sucrose formulations to enhance glass stability when exposed to temperature and humidity. Tg and onset glass transition humidity (RHg) parameters were experimentally determined as indicators of formulation glass stability with respect to temperature and humidity, respectively. A mixture design of experiment approach was employed to determine the influence of insulin, sucrose and polymer composition on formulation Tg and RHg. Statistical regression models were established to evaluate the relationship between formulation composition and the corresponding glass transition parameters, Tg and RHg. Phase separation noted for PVPVA-containing formulations, undermined regression model goodness of fit. Insulin content was shown to have a negative effect on both formulation Tg and RHg. Formulation Tg appeared to be influenced by insulin’s dynamical temperature rather than a previously reported insulin Tg value. Insulin-sucrose and insulin-polymer interactive effects resulted in increased Tg and RHg values, indicating enhanced formulation glass stability. Formulation optimization for maximized Tg and RHg identified a formulation composed of 26 % w/w insulin, 40 % w/w sucrose, and 34 % w/w PVP, with a predicted Tg of 82 °C and RHg of 60 % RH. The enhanced glass stability of the ternary insulin-sucrose-polymer formulations offers potential advantages for the manufacture, storage and handling of peptide containing oral dosage forms.
冻干无定形肽制剂的玻璃稳定性,用于合并到固体口服剂型中,需要针对制造,储存和处理温度和湿度的挑战进行稳定。在胰岛素-蔗糖配方中加入高玻璃化转变温度(Tg)聚合物,聚乙烯吡咯烷酮(PVP)和聚乙烯吡咯烷酮-醋酸乙烯酯(PVPVA),以提高暴露在温度和湿度下的玻璃稳定性。实验确定Tg和起始玻璃转变湿度(RHg)参数分别作为配方玻璃稳定性的温度和湿度指标。采用实验法的混合设计,确定胰岛素、蔗糖和聚合物组成对配方Tg和RHg的影响。建立统计回归模型,评价配方成分与相应玻璃化转变参数Tg和RHg之间的关系。相分离注意到pvpva含有配方,破坏了回归模型的拟合优度。胰岛素含量对Tg和RHg的形成均有负面影响。制剂Tg似乎受到胰岛素动态温度的影响,而不是先前报道的胰岛素Tg值。胰岛素-蔗糖和胰岛素-聚合物的相互作用导致Tg和RHg值增加,表明配方玻璃稳定性增强。为实现Tg和RHg的最优化,确定了一个由26% w/w胰岛素、40% w/w蔗糖和34% w/w PVP组成的配方,预测Tg为82°C, RHg为60% RH。三元胰岛素-蔗糖-聚合物配方的玻璃稳定性增强,为含有口服剂型的肽的制造、储存和处理提供了潜在的优势。
{"title":"Design of co-lyophilised ternary insulin-sucrose-polymer systems with enhanced amorphous glass stability","authors":"Claudia Giannachi ,&nbsp;Evin Allen ,&nbsp;Sonja Vucen ,&nbsp;Abina Crean","doi":"10.1016/j.ejps.2026.107450","DOIUrl":"10.1016/j.ejps.2026.107450","url":null,"abstract":"<div><div>The glass stability of lyophilized amorphous peptide formulations, intended for incorporation into solid oral dosage forms, require stabilisation against the challenges of manufacturing, storage and handling temperature and humidity. High glass transition temperature (Tg) polymers, polyvinylpyrrolidone (PVP) and polyvinylpyrrolidone-vinyl acetate (PVPVA), were added to insulin-sucrose formulations to enhance glass stability when exposed to temperature and humidity. Tg and onset glass transition humidity (RHg) parameters were experimentally determined as indicators of formulation glass stability with respect to temperature and humidity, respectively. A mixture design of experiment approach was employed to determine the influence of insulin, sucrose and polymer composition on formulation Tg and RHg. Statistical regression models were established to evaluate the relationship between formulation composition and the corresponding glass transition parameters, Tg and RHg. Phase separation noted for PVPVA-containing formulations, undermined regression model goodness of fit. Insulin content was shown to have a negative effect on both formulation Tg and RHg. Formulation Tg appeared to be influenced by insulin’s dynamical temperature rather than a previously reported insulin Tg value. Insulin-sucrose and insulin-polymer interactive effects resulted in increased Tg and RHg values, indicating enhanced formulation glass stability. Formulation optimization for maximized Tg and RHg identified a formulation composed of 26 % w/w insulin, 40 % w/w sucrose, and 34 % w/w PVP, with a predicted Tg of 82 °C and RHg of 60 % RH. The enhanced glass stability of the ternary insulin-sucrose-polymer formulations offers potential advantages for the manufacture, storage and handling of peptide containing oral dosage forms.</div></div>","PeriodicalId":12018,"journal":{"name":"European Journal of Pharmaceutical Sciences","volume":"218 ","pages":"Article 107450"},"PeriodicalIF":4.7,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146044009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Empowering the Pharmaceutical Workforce for the Digital Future. 赋能制药员工,迎接数字化未来。
IF 4.7 3区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-21 DOI: 10.1016/j.ejps.2026.107449
Natalie Maclean, Susanna Abrahmsén-Alami, Catriona Clark, Frederik Dörr, Alastair Florence, Jarkko Ketolainen, Morten Lindow, Jérôme Mantanus, Jukka Rantanen, Gavin Reynolds, Amy Robertson, Daniel Markl

The pharmaceutical industry is undergoing a rapid digital transformation. These changes are reshaping drug substance and drug product development and manufacturing, creating both opportunities and challenges that span pharmaceutical sciences, data science, and automation engineering. However, significant skills gaps persist, limiting the sector's ability to fully leverage digital technologies and sustain innovation. This paper explores the shifting digital and data science skills needs within the pharmaceutical industry, with a focus on industrial pharmacy and pharmaceutical sciences in the UK and Europe. We examine the key technological transformations reshaping the sector, the evolution of job roles, and the attributes required of the future workforce. Building on these insights, we propose an integrated approach to skills development that spans the entire career lifecycle - from embedding digital competencies in higher education to supporting lifelong learning through flexible, industry-aligned continuing professional development. Addressing these skills gaps requires coordinated action from academia, industry, and policymakers. By fostering a collaborative, interdisciplinary, and adaptive learning ecosystem, the pharmaceutical sector can equip its workforce to thrive in a rapidly changing landscape and continue improving global health and wellbeing.

制药行业正在经历快速的数字化转型。这些变化正在重塑原料药和药品的开发和制造,为制药科学、数据科学和自动化工程创造了机遇和挑战。然而,巨大的技能差距仍然存在,限制了该行业充分利用数字技术和持续创新的能力。本文探讨了制药行业中不断变化的数字和数据科学技能需求,重点关注英国和欧洲的工业制药和制药科学。我们研究了重塑该行业的关键技术变革、工作角色的演变以及未来劳动力所需的属性。基于这些见解,我们提出了一种跨越整个职业生命周期的综合技能开发方法——从在高等教育中嵌入数字能力,到通过灵活的、与行业一致的持续专业发展支持终身学习。解决这些技能差距需要学术界、工业界和政策制定者采取协调一致的行动。通过培育协作、跨学科和适应性学习生态系统,制药行业可以使其员工在快速变化的环境中茁壮成长,并继续改善全球健康和福祉。
{"title":"Empowering the Pharmaceutical Workforce for the Digital Future.","authors":"Natalie Maclean, Susanna Abrahmsén-Alami, Catriona Clark, Frederik Dörr, Alastair Florence, Jarkko Ketolainen, Morten Lindow, Jérôme Mantanus, Jukka Rantanen, Gavin Reynolds, Amy Robertson, Daniel Markl","doi":"10.1016/j.ejps.2026.107449","DOIUrl":"https://doi.org/10.1016/j.ejps.2026.107449","url":null,"abstract":"<p><p>The pharmaceutical industry is undergoing a rapid digital transformation. These changes are reshaping drug substance and drug product development and manufacturing, creating both opportunities and challenges that span pharmaceutical sciences, data science, and automation engineering. However, significant skills gaps persist, limiting the sector's ability to fully leverage digital technologies and sustain innovation. This paper explores the shifting digital and data science skills needs within the pharmaceutical industry, with a focus on industrial pharmacy and pharmaceutical sciences in the UK and Europe. We examine the key technological transformations reshaping the sector, the evolution of job roles, and the attributes required of the future workforce. Building on these insights, we propose an integrated approach to skills development that spans the entire career lifecycle - from embedding digital competencies in higher education to supporting lifelong learning through flexible, industry-aligned continuing professional development. Addressing these skills gaps requires coordinated action from academia, industry, and policymakers. By fostering a collaborative, interdisciplinary, and adaptive learning ecosystem, the pharmaceutical sector can equip its workforce to thrive in a rapidly changing landscape and continue improving global health and wellbeing.</p>","PeriodicalId":12018,"journal":{"name":"European Journal of Pharmaceutical Sciences","volume":" ","pages":"107449"},"PeriodicalIF":4.7,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146040703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European Journal of Pharmaceutical Sciences
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1